Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsFanyue Meng, Fengcai Zhu, Fan Gao et al.|Signal Transduction and Targeted Therapy|2021Cited by 36
B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman PrimatesYu Bai, Miao Xu, Qunying Mao et al.|Microbiology Spectrum|2022Cited by 10